ConductScience.org, home

Paper34735653

Adult T-Cell Leukemia: a Comprehensive Overview on Current and Promising Treatment Modalities.

Hleihel R and 5 others. Curr Oncol Rep, 2021. Cited by 20 papers, by iCite.

Cite this record

ConductScience Library. Adult T-Cell Leukemia: a Comprehensive Overview on Current and Promising Treatment Modalities. Papers, record 34735653. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/34735653

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Adult T-Cell Leukemia: a Comprehensive Overview on Current and Promising Treatment Modalities.
PubMed
Journal
Curr Oncol Rep
PubMed
Year
2021
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
20
iCite
Relative citation ratio, by iCite
1.32
iCite
Revised in PubMed
2026-10-10
PubMed

Authors6

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Hleihel RRita
2Akkouche AAbdou
3Skayneh HHala
4Hermine OOlivier
5Bazarbachi AAli
6El Hajj HHiba

Source PubMed

Download CSV of authors

Topics6

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antineoplastic Agents, ImmunologicalMajor topic
Hematopoietic Stem Cell TransplantationMajor topic
Leukemia-Lymphoma, Adult T-CellMajor topic
Antibodies, Monoclonal, Humanized
Humans
Prognosis

References134

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
19864171Arsenic trioxide and interferon-alpha synergize to induce cell cycle arrest and apoptosis in human T-cell lymphotropic virus type I-transformed cells.Blood1999https://conductscience.org/library/papers/9864171PubMed
212627852Deoxycoformycin-containing combination chemotherapy for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study (JCOG9109).Int J Hematol2003https://conductscience.org/library/papers/12627852PubMed
318948574Effective treatment of a murine model of adult T-cell leukemia using depsipeptide and its combination with unmodified daclizumab directed toward CD25.Blood2009https://conductscience.org/library/papers/18948574PubMed
420479287Transplantation of allogeneic hematopoietic stem cells for adult T-cell leukemia: a nationwide retrospective study.Blood2010https://conductscience.org/library/papers/20479287PubMed
51751370Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma. A report from the Lymphoma Study Group (1984-87).Br J Haematol1991https://conductscience.org/library/papers/1751370PubMed
625029232Outcome of patients with HTLV-1-associated adult T-cell leukemia/lymphoma after SCT: a retrospective study by the EBMT LWP.Bone Marrow Transplant2014https://conductscience.org/library/papers/25029232PubMed
727621400Multicenter Phase II Study of Lenalidomide in Relapsed or Recurrent Adult T-Cell Leukemia/Lymphoma: ATLL-002.J Clin Oncol2016https://conductscience.org/library/papers/27621400PubMed
823962110The combination of arsenic, interferon-alpha, and zidovudine restores an "immunocompetent-like" cytokine expression profile in patients with adult T-cell leukemia lymphoma.Retrovirology2013https://conductscience.org/library/papers/23962110PubMed
917968021VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study JCOG9801.J Clin Oncol2007https://conductscience.org/library/papers/17968021PubMed
1027322308HTLV-1 Infection and Adult T-Cell Leukemia/Lymphoma-A Tale of Two Proteins: Tax and HBZ.Viruses2016https://conductscience.org/library/papers/27322308PubMed
1126735971HTLV-1 bZIP Factor Impairs Anti-viral Immunity by Inducing Co-inhibitory Molecule, T Cell Immunoglobulin and ITIM Domain (TIGIT).PLoS Pathog2016https://conductscience.org/library/papers/26735971PubMed
1219411628Phase 2 study of the efficacy and safety of the combination of arsenic trioxide, interferon alpha, and zidovudine in newly diagnosed chronic adult T-cell leukemia/lymphoma (ATL).Blood2009https://conductscience.org/library/papers/19411628PubMed
1315522654New therapeutic approaches for adult T-cell leukaemia.Lancet Oncol2004https://conductscience.org/library/papers/15522654PubMed
1429545256Epidemiology, clinical features, and outcome of HTLV-1-related ATLL in an area of prevalence in the United States.Blood Adv2018https://conductscience.org/library/papers/29545256PubMed
157492783Characterization of T cells immortalized by Tax1 of human T-cell leukemia virus type 1.Blood1995https://conductscience.org/library/papers/7492783PubMed
1631617432Phase 1 study of the Aurora kinase A inhibitor alisertib (MLN8237) combined with the histone deacetylase inhibitor vorinostat in lymphoid malignancies.Leuk Lymphoma2020https://conductscience.org/library/papers/31617432PubMed
1720585095Meta-analysis on the use of zidovudine and interferon-alfa in adult T-cell leukemia/lymphoma showing improved survival in the leukemic subtypes.J Clin Oncol2010https://conductscience.org/library/papers/20585095PubMed
1821505188Effects of valproate on Tax and HBZ expression in HTLV-1 and HAM/TSP T lymphocytes.Blood2011https://conductscience.org/library/papers/21505188PubMed
1922312108Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study.J Clin Oncol2012https://conductscience.org/library/papers/22312108PubMed
2021228036Overexpression of Enhancer of zeste homolog 2 with trimethylation of lysine 27 on histone H3 in adult T-cell leukemia/lymphoma as a target for epigenetic therapy.Haematologica2011https://conductscience.org/library/papers/21228036PubMed

See all 134 referencesDownload CSV of references

Cited by13

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 20 citations.

PMIDTitleJournalYearIn PapersSource
42511509Investigating the Mechanisms Underlying Cell Death Induction by a Tributyltin Molecule in HTLV-1-Infected Cells Dependent or Not on IL-2 as a Growth Factor.Int J Mol Sci2026https://conductscience.org/library/papers/42511509PubMed
42240309HTLV-1 Tax and HBZ cooperatively promote leukemogenesis through miR-155-mediated PTEN suppression and PI3K-Akt activation.J Virol2026https://conductscience.org/library/papers/42240309PubMed
41599396Cytotoxic Effects of a Triorganotin Derivative on HTLV-1-Infected Cells at Different Immortalization/Transformation Stages In Vitro.Molecules2026https://conductscience.org/library/papers/41599396PubMed
40551258Unveiling the anticancer potential of SGLT-2 inhibitors: mechanisms and prospects in clinical oncology-a narrative review.Eur J Med Res2025https://conductscience.org/library/papers/40551258PubMed
39633427Evaluation of ALKBH2 and ALKBH3 gene regulation in patients with adult T-cell leukemia/lymphoma.Virol J2024https://conductscience.org/library/papers/39633427PubMed
39008152Peptides for microbe-induced cancers: latest therapeutic strategies and their advanced technologies.Cancer Metastasis Rev2024https://conductscience.org/library/papers/39008152PubMed
37892225Understanding the Immunopathology of HTLV-1-Associated Adult T-Cell Leukemia/Lymphoma: A Comprehensive Review.Biomolecules2023https://conductscience.org/library/papers/37892225PubMed
37531001Momordica charantia phytoconstituents can inhibit human T-lymphotropic virus type-1 (HTLV-1) infectivity in vitro and in vivo.J Neurovirol2025https://conductscience.org/library/papers/37531001PubMed
37137914Primary cells from patients with adult T cell leukemia/lymphoma depend on HTLV-1 Tax expression for NF-κB activation and survival.Blood Cancer J2023https://conductscience.org/library/papers/37137914PubMed
36428851Comparative Genomic Hybridization and Transcriptome Sequencing Reveal Genes with Gain in Acute Lymphoblastic Leukemia: JUP Expression Emerges as a Survival-Related Gene.Diagnostics (Basel)2022https://conductscience.org/library/papers/36428851PubMed
35935975Interplay between innate immunity and the viral oncoproteins Tax and HBZ in the pathogenesis and therapeutic response of HTLV-1 associated adult T cell leukemia.Front Immunol2022https://conductscience.org/library/papers/35935975PubMed
35686099The Roles of FHL3 in Cancer.Front Oncol2022https://conductscience.org/library/papers/35686099PubMed
35631768Prediction of the Adult T-Cell Leukemia Inhibitory Activity of Blueberry Leaves/Stems Using Direct-Injection Electron Ionization-Mass Spectrometry Metabolomics.Plants (Basel)2022https://conductscience.org/library/papers/35631768PubMed

Download CSV of cited by

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
HBZ3050PubTator's text mininghttps://conductscience.org/library/genes/3050

Source NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/34735653

GET https://conductscience.org/api/papers/v1/34735653/references?page=2